Clinical Research Directory

Inclusion Criteria: * Women aged 60-85 years * Breast cancer survivors, stages I-IV without clinical suspicion or evidence of brain metastasis * Completion of last taxane and/or platinum chemotherapy treatment ≥ 6 months prior, but chemotherapy was received after the age of 60. Taxane combined with a history of platinum, anthracycline and/or cyclophosphamide is permitted. Active anti-estrogen therapy, Anti-HER2, and CDK 4/6 inhibitors are permitted * Ability to walk unassisted for 60 seconds * Proficient in English * Without neurological disease, aside from chemotherapy induced peripheral neuropathy (CIPN) or chemotherapy related cognitive dysfunction (CRCD) * No history of a second cancer besides skin cancer Exclusion Criteria: * Hospitalization within the past three months due to acute illness or as the result of a musculoskeletal injury significantly affecting gait or balance * Any unstable medical condition * Diagnosis of a gait disorder, Parkinson's disease, Alzheimer's disease or dementia, multiple sclerosis, previous stroke or other neurodegenerative disorder * Chronic vertigo * Myocardial infarction within the past six months * History of immune check point inhibitor therapy * Any history of brain or cervical spine surgery, known hearing, visual, or vestibular impairment * Active neurotoxic chemotherapy (taxane, platinum or vinca alkaloid) or radiation therapy * Contraindications to transcranial direct simulation (tDCS), including reported seizure within the past two years,, metal objects in head or neck, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, cochlear implant, vagus nerve stimulator, spinal cord stimulator, pacemakers, and intracardiac devices, etc.), or the presence of any active dermatological condition, such as eczema, on the scalp